Modality
ADC
MOA
SOS1i
Target
TNFα
Pathway
PI3K/AKT
HNSCCAsthmaSchizophrenia
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
Sep 2022
→ Nov 2030
Phase 2Current
NCT03340509
2,399 pts·Schizophrenia
2024-09→2026-08·Completed
NCT05899036
1,576 pts·Schizophrenia
2022-09→2030-11·Terminated
3,975 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-134mo awayPh3 Readout· Schizophrenia
2030-11-054.6y awayPh3 Readout· Schizophrenia
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
P2/3
Complet…
Catalysts
Ph3 Readout
2026-08-13 · 4mo away
Schizophrenia
Ph3 Readout
2030-11-05 · 4.6y away
Schizophrenia
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03340509 | Phase 2/3 | Schizophrenia | Completed | 2399 | UPDRS |
| NCT05899036 | Phase 2/3 | Schizophrenia | Terminated | 1576 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| MRN-8225 | Moderna | Preclinical | TNFα |